Fecal Calprotectin is a Useful Biomarker for Predicting the Clinical Outcome of Granulocyte and Monocyte Adsorptive Apheresis in Ulcerative Colitis Patients: A Prospective Observation Study.

Nobuhiro Ueno (✉ u-eno@asahikawa-med.ac.jp)
Asahikawa Medical University

Yuya Sugiyama
Asahikawa Medical University

Yu Kobayashi
Asahikawa Medical University

Yuki Murakami
Asahikawa Medical University

Takuya Iwama
Asahikawa Medical University

Takahiro Sasaki
Asahikawa Medical University

Takehito Kunogi
Asahikawa Medical University

Keitaro Takahashi
Asahikawa Medical University

Kazuyuki Tanaka
Asahikawa Kosei Hospital

Katsuyoshi Ando
Asahikawa Medical University

Shin Kashima
Asahikawa Medical University

Yuhei Inaba
Asahikawa City Hospital

Kentaro Moriichi
Asahikawa Medical University

Hiroki Tanabe
Asahikawa Medical University

Masaki Taruishi
Asahikawa City Hospital
Keywords: Fecal calprotectin, Ulcerative colitis, Biomarker, Granulocyte/Monocyte Apheresis (GMA), Endoscopic remission, Clinical remission, Colonoscopy

DOI: https://doi.org/10.21203/rs.3.rs-154609/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Granulocyte and monocyte adsorptive apheresis (GMA) is widely used as a remission induction therapy for active ulcerative colitis (UC) patients. However, there are no available biomarkers for predicting the clinical outcome of GMA. We investigated the utility of Fecal calprotectin (FC) as a biomarker for predicting the clinical outcome during GMA therapy in active UC patients.

**Methods:** In this multicenter prospective observation study, all patients received 10 sessions of GMA, twice a week, for 5 consecutive weeks. FC was measured at entry, one week, two weeks, and at the end of GMA. Colonoscopy was performed at entry and after GMA. The clinical activity was assessed based on the partial Mayo score when FC was measured. Clinical remission (CR) was defined as a partial Mayo score of \( \leq 2 \) and endoscopic remission (ER) was defined as Mayo endoscopic subscore of either 0 or 1. We analyzed the relationships between the clinical outcome (CR and ER) and the change in FC concentration.

**Result:** Twenty-six patients were included in this study. The overall CR and ER rates were 50.0% and 19.2%, respectively. After GMA, the median FC concentration in patients with ER was significantly lower than that in patients without ER (469 mg/kg vs. 3107 mg/kg, p=0.03). When the cut-off value of FC concentration was set at 1150 mg/kg for assessing ER after GMA, the sensitivity and specificity were 0.8 and 0.81, respectively. The FC concentration had significantly decreased by one week. An ROC analysis demonstrated that the reduction rate of FC (\( \Delta FC \)) at 1 week was the most accurate predictor of CR at the end of GMA (AUC=0.852, P=0.002). When the cut-off value of \( \Delta FC \) was set at \( \leq 40\% \) at 1 week for predicting CR at the end of GMA, the sensitivity and specificity were 76.9% and 84.6%, respectively.

**Conclusion:** We evaluated the utility of FC as a biomarker for assessing ER after GMA and predicting CR in the early phase during GMA in patients with active UC. Our findings will benefit patients with active UC by allowing them to avoid unnecessary invasive procedures and will help establish new strategies for GMA.

Introduction

Ulcerative colitis (UC) is a chronic intestinal disorder of unknown etiology and characterized by a relapsing and remitting course.\(^1\)(\(^2\)) The diagnosis and assessment of the disease activity has been based on clinical symptoms, laboratory measurements, findings of endoscopy and pathological examinations.\(^1\) Therefore, the development of a non-invasive and simple biomarker for evaluating the disease activity is considered necessary for the clinical management of UC.

Calprotectin is a complex of the mammalian proteins S100A8 and S100A9 found in the cytosol of human neutrophils, monocytes and macrophages.\(^3\) It is released into the intestinal lumen by cellular degranulation of neutrophils in response to intestinal mucosal inflammation; thus, the fecal calprotectin (FC) directly reflects the migration of neutrophils into the intestinal mucosa in inflammatory bowel
diseases (IBD).\(^4\) Calprotectin is very stable and resistant to degradation and can be detected in stool for three days when left at room temperature.\(^5\)(\(^6\)\) Previous studies have reported that the FC concentration is well correlated with endoscopic severity\(^7\)(\(^8\)) and histological findings\(^9\) and can also predict clinical relapse during maintenance therapy for UC.\(^10\)(\(^11\)) Thus, in the clinical setting, FC is widely used as a non-invasive biomarker for monitoring intestinal inflammation in UC. Several studies have further explored its value as a biomarker for predicting and assessing the clinical response to induction therapy in patients with active UC.\(^12\)–\(^16\) However, the utility of the FC concentration as a biomarker for predicting the clinical outcome during remission induction therapy has not been established.

Granulocyte and monocyte adsorptive apheresis (GMA) with an Adacolumn (JIMRO Co., Takasaki, Japan) has been applied as a non-pharmacological treatment strategy. GMA is widely used as a remission induction therapy for patients with active UC in Japan and is also available in the European Union. The mechanism underlying GMA involves the Adacolumn which is filled with cellulose acetate carrier beads, interacting with fragment crystallizable-gamma receptor (Fc\(\gamma\)R) expressed at the surface of leukocytes and selectively adsorbing granulocytes, monocytes/macrophages, a significant fraction of platelets and a small number of lymphocytes from circulation.\(^17\)(\(^18\)) Numerous reports have described the clinical efficacy and safety of GMA in patients with active UC.\(^19\)–\(^28\) However, it remains difficult to evaluate the clinical efficacy of GMA, as there are no available biomarkers for assessing and predicting the clinical response.

We hypothesized that FC might be a useful biomarker for evaluating the clinical efficacy of GMA, as GMA with an Adacolumn selectively adsorbs granulocytes, including neutrophils, which are rich in calprotectin. Very few clinical studies have found FC to be useful as a biomarker for GMA, and its value for predicting the clinical outcome during GMA therapy remains unclear. Measuring the FC concentration may allow for invasive procedures to be avoided if it can reasonably estimate the clinical outcome during GMA. Thus, the present study investigated the relationship between the clinical outcome and time-dependent change in the FC level during GMA and evaluated the utility of the FC concentration as a biomarker for predicting the clinical outcome during GMA in patients with active UC.

**Materials And Methods**

**Study design and ethics**

This multicenter prospective observational study was conducted to assess the utility of FC as a biomarker for assessing the clinical efficacy and mucosal healing during GMA with an Adacolumn in patients with active UC by three independent institutes in Japan from October 2015 to March 2019. These institutes included Asahikawa Kosei General Hospital, Asahikawa City Hospital and Asahikawa Medical University. The protocol was reviewed and approved by the Ethics Committees at Asahikawa Medical University (approved number 15106) and each institution. All patients provided their written informed consent in accordance with the Declaration of Helsinki before commencement of this study.
Patients

The inclusion criteria were as follows: (1) a diagnosis of UC, (2) $\geq 16$ years of age; and (3) any clinical symptoms with a partial Mayo (pMayo) score of $\geq 3$ (stool frequency [0–3], rectal bleeding [0–3] and Physician's global assessment [0–3]). The exclusion criteria were as follows: (1) contraindication of GMA therapy (according to our hospital criteria: neutrophil count $< 1500/\text{mm}^3$, hemoglobin $< 10 \text{ g/dL}$ or a history of allergic reaction to anticoagulant or a serious cardiac, pulmonary, hepatic or renal disorder), (2) total colectomy, and (3) taking $> 2$ oral NSAID tablets per week.

Patients receiving 5-aminosalicylic acid preparation, immunosuppressors, corticosteroids or biologic at entry were able to continue taking these medications at the same dose and frequency. Additional new medication for UC was not allowed during GMA. However, for patients receiving corticosteroids at entry, the dose could be reduced or treatment could be stopped according to improvement during GMA. When a patient's condition worsened or remained unchanged, GMA could be withdrawn and another therapy including corticosteroids, immunosuppressants, biologics or surgery could be initiated, as necessary. The following parameters at entry were recorded in all patients as baseline characteristics: age, gender, body weight, history, duration of disease, extent of UC, current exacerbation, and concomitant medication.

GMA therapy with an Adacolumn

GMA with an Adacolumn (JIMRO Co., Takasaki, Japan) is approved as remission induction therapy for patients with active UC by the Japan Ministry of Health. All patients in our study received 10 sessions of GMA with an Adacolumn twice a week for 5 consecutive weeks. Each patient's blood via venipuncture of an antecubital vein entered the Adacolumn and then was delivered back to the patient via the column outflow line. The GMA regimen consisted of a standard protocol, filtering 1800 ml per session at a rate of 30 ml/min for 60 min. An optimum dose of sodium heparin (5000 units/session) was administered during GMA as an anticoagulant. All adverse events that occurred during GMA were recorded.

Biomarker measurement

FC was measured at entry, 1 week, 2 weeks, at the end of GMA and on the day of endoscopy within 24 weeks after GMA. All patients were required to collect a stool sample within two days before their clinical visit and store it at room temperature. The stool samples were sent to Thermo Fisher Scientific (Tokyo, Japan) in a frozen state, and the calprotectin concentration was measured in a blinded manner to determine the clinical and endoscopic profiles. After thawing, the stool samples were homogenized by mixing with a predefined extraction buffer volume. After centrifugation, the supernatants were subjected to a fluorescence enzyme immunoassay using EliA Calprotectin 2. The measurements were performed in duplicate, and the average value was used for the analyses. Laboratory values, including the white blood cell (WBC) count and C reactive protein (CRP) level were also measured at the same time points as FC measurement: at entry, one and two weeks and at the end of GMA and on the day when endoscopy was performed within 24 weeks after GMA.
The assessment of the clinical efficacy of GMA with Adaculumn

Clinical activity was assessed using the pMayo score at the same time points as FC was monitored: at entry, one week, two weeks, and at the end of GMA. Clinical remission (CR) was defined as a pMayo score of $\leq 2$ and a score of $\leq 1$ for all subscores (stool frequency [0–3], rectal bleeding [0–3] and Physician's global assessment [0–3]). Endoscopy was performed before starting GMA and within 24 weeks after finishing GMA. The endoscopic activity was assessed using the Mayo endoscopic subscore (MES) at the most severely inflamed segment of the colon. Endoscopic remission (ER) which refers to mucosal healing, was defined as MES 0 or 1.

Endpoints

The primary endpoint was the relationship between the ER and the FC concentration after GMA therapy. The secondary endpoints were the relationships between the CR and the time-dependent changes in the pMayo score, FC concentration, WBC count and CRP value during GMA therapy.

Statistical analyses

The numerical data presented as the medians with interquartile ranges (IQRs). The comparison of demographic characteristics between the CR and non-CR groups was performed using the Mann-Whitney U-test or chi-square test. Wilcoxon's test was used for nonparametric, paired and continuous variables, such as the time-dependent change in each marker during GMA. Receiver operating characteristics (ROC) curves with their area under the curve (AUC) were used to assess the cut-off value of endoscopic remission and predictors of CR with GMA therapy. The point with the largest AUC was defined as the point having the greatest association with predicting the CR with GMA therapy. The optimum cut-off value was determined as the nearest point from upper left corner to the point on the ROC curve. A P value $< 0.05$ was considered statistically significant. Every statistical analysis was performed using the SPSS for Windows (SPSS Inc., Chicago, IL, USA).

Results

Patients’ characteristics

A total 36 of patients with active UC were enrolled in this study. Ten patients were excluded (administration of additional medication during GMA therapy [$n = 5$]; issues with laboratory results [$n = 2$]; deviation from protocol [$n = 2$]; total colectomy [$n = 1$]); thus, 26 patients were included in the study. The baseline characteristics of the 26 eligible patients in this study are shown in Table 1.
Table 1
The baseline characteristics of the 26 eligible patients in this study

| Baseline characteristics                  | N     | 26   |
|-------------------------------------------|-------|------|
| **Age**                                   | median (min-max) | 39 (16–70) |
| **Gender - male**                         | N (%) | 11(42.3) |
| **Body weight, kg**                       | median (min-max) | 51.9 (37.7–87.7) |
| **Duration of disease, month**            | median (min-max) | 58 (10–159) |
| **Extent of UC (Montreal classification)**|       |      |
| left side colitis (E2)                    | N     | 10   |
| pancolitis (E3)                           | N     | 16   |
| **Disease activity**                      |       |      |
| pMayo score                               | median (IQR) | 6 (5.25-7) |
| MES                                       | median (IQR) | 2 (2–2) |
| **Concomitant medication**                |       |      |
| 5-aminosalicylic acid                     | N (%) | 23 (88.4) |
| Corticosteroid                            | N (%) | 8 (30.7) |
| Immunosuppressant                         | N (%) | 11 (42.3) |
| Anti-TNF-alpha agent                      | N (%) | 5 (19.2) |
| **Biomarker**                             |       |      |
| FC (mg/kg)                                | median (IQR) | 11294.5 (5116.75-18755.25) |
| WBC count                                 | median (IQR) | 6350 (4935–7945) |
| CRP (mg/dL)                               | median (IQR) | 0.58 (0.1–1.39) |

The overall efficacy and safety of GMA with an Adacolumn and the baseline characteristics of CR patients.

According to the clinical assessment, 13 patients achieved a CR and 13 did not achieve a CR at the end of treatment. According to the endoscopic assessment, among the 13 patients with a CR, 5 achieved an ER after GMA therapy. The overall CR and ER rates were 50.0% and 19.2%, respectively. There were no adverse events in the present study.

The patients were divided into the CR and non-CR groups by the assessment of the clinical activity based on the pMayo score at the end of GMA. The baseline characteristics of the groups at the start of GMA are shown in Table 2. There were no significant differences in age, gender, body weight or extent of UC.
However, the disease duration was significantly longer in the CR group than in the non-CR group: 118 vs. 28 months ($P = 0.001$). There was no significant difference in the pMayo score between the CR and non-CR groups, although the MES at the start of GMA in the CR group was significantly lower than that in the non-CR group: 2 vs. 2 ($P = 0.03$). There was no significant difference in the ratio of concomitant medication, such as 5-aminosalicylic acid, corticosteroids, immunosuppressants and anti-TNF-α agents, or in the biomarkers of FC, WBC count and CRP at the start of GMA between the CR and non-CR groups.
Table 2
The comparison of baseline characteristics between the CR and non-CR groups

| Baseline characteristics                  | CR group | Non-CR group | p-value |
|-------------------------------------------|----------|--------------|---------|
| Number of cases                           | N 13     | 13           |         |
| Age                                       | Median   | 53 (25–68)  | 23 (16–70) | 0.09  |
|                                           | (min-max)|             |         |
| Gender - male                             | N (%)    | 4            | 7       | 0.234 |
| Body weight, kg                           | Median   | 47           | 55      | 0.48  |
|                                           | (min-max)|(43.7–68.2)  | (37.7–83.3)|     |
| Duration of disease, month                | Median   | 118          | 28      | 0.001 |
|                                           | (min-max)|(12–159)     | (6-130) |       |
| Extent of UC (Montreal classification)    |          |             |         | 0.42  |
| left side colitis (E2)                    | N 4      | 6            |         |       |
| pancolitis (E3)                           | N 9      | 7            |         |       |
| Disease activity                          |          |             |         |       |
| pMayo score                               | Median   | 6            | 7       | 0.76  |
|                                           | (IQR)    | (6–7)        | (5–7)   |       |
| MES                                       | Median   | 2            | 2       | 0.03  |
|                                           | (IQR)    | (2–2)        | (2–3)   |       |
| Concomitant medication                    |          |             |         |       |
| 5-aminosalicylic acid                     | N (%)    | 12           | 10      |       |
| Corticosteroid                            | N (%)    | 4            | 3       | 0.658 |
| Immunosuppressant                         | N (%)    | 5            | 8       | 0.239 |
| Anti-TNF-alpha agent                      | N (%)    | 3            | 2       | 0.619 |
| Biomarker at entry                        |          |             |         |       |
| FC (mg/kg)                                | Median   | 15669        | 9496    | 0.07  |
|                                           | (IQR)    | (7280–20017) | (1073–14015) |       |
| WBC count                                 | Median   | 5980         | 7290    | 0.29  |
|                                           | (IQR)    | (4760–6970)  | (5200–8250) |       |
Baseline characteristics

|                      | CR group | Non-CR group | p-value |
|----------------------|----------|--------------|---------|
| CRP (mg/dL)          | Median   | 0.66         | 0.36    | 0.53    |
|                      | (IQR)    | (0.1–4.56)   | (0.1–1.26) |

Primary endpoint: Relationship between ER and the FC level after GMA therapy

The FC concentration after GMA was well correlated with the MES (R = 0.56, p = 0.002) (Fig. 1A). The 26 patients were divided into the ER (n = 5) and a non-ER (n = 21) group. The median FC concentration of the ER group was significantly lower than that of the non-ER group after GMA (469 mg/kg vs. 3107 mg/kg, p = 0.03) (Fig. 1B). An ROC analysis showed that when the cut-off value of FC concentration was set at 1150 mg/kg for assessing ER after GMA, the sensitivity, specificity, positive predictive value (PPV) and accuracy were 0.8, 0.81, 0.5 and 0.8, respectively.

Secondary endpoint: Relationship between CR and time-dependent changes in the pMayo score, FC level, WBC count and CRP during GMA therapy

The time-dependent changes in the pMayo score, FC concentration, WBC count and CRP value during GMA are shown in Fig. 2. A time-dependent decline in the pMayo score during GMA was observed in both the CR and non-CR groups. In particular, the pMayo score at 1 week was significantly lower than at entry in both the CR and non-CR groups (p < 0.01, p < 0.05). A time-dependent decrease in the FC concentration during GMA was only observed in the CR group, and the FC concentration at 1 week was significantly lower than that at entry (p < 0.01). A time-dependent change in the WBC count was not observed during GMA in either the CR or non-CR groups. A time-dependent decrease in the CRP value during GMA was only observed in the CR group, and the CRP value at 1 week was significantly lower than that at entry (p < 0.05) (Fig. 2A).

Both the FC concentration and CRP value at entry showed a wide range of measurements. FC is known to have wide variability, which is influenced by various factors. CRP is also affected by bacterial infections in the internal and external intestine. We therefore also analyzed the reduction rates of FC (ΔFC) and CRP (ΔCRP) to assess the accuracy of these biomarkers in predicting the efficacy of GMA. Similar to findings for the FC concentration and CRP value, time-dependent decreases in ΔFC and ΔCRP during GMA were only observed in the CR group, and the ΔFC and ΔCRP values at 1 week were significantly lower than at entry (p < 0.01, 0.05) (Fig. 2B). The pFC and ΔCRP at one week showed remarkable reductions from their values at entry; thus, they were considered potential predictors of CR at the end of GMA.
An ROC analysis showed that ΔFC at 1 week was the most accurate predictor of CR at the end of GMA (AUC = 0.852, P = 0.002) among the pMayo score, FC concentration, CRP value and ΔCRP at 1 week (AUC = 0.842, 0.663, 0.666 and 0.784. P = 0.003, 0.158, 0.151 and 0.014) (Fig. 3). The cut-off value of each marker and the sensitivity, specificity, PPV and accuracy are shown in Table 3. When the cut-off value of ΔFC at 1 week for predicting CR at the end of GMA therapy was set at ≤ 40%, the sensitivity, specificity, PPV and accuracy were 76.9%, 84.6%, 83.3% and 80.7%, respectively (Table 3).

Table 3
The cut-off value of each marker and the sensitivity, specificity, positive predictive value and accuracy.

| Marker   | Sensitivity | Specificity | PPV  | Accuracy |
|----------|-------------|-------------|------|----------|
| PMayo ≤ 4| 0.615       | 0.923       | 0.888| 0.769    |
| PMayo ≤ 5| 0.769       | 0.846       | 0.833| 0.807    |
| PMayo ≤ 6| 0.846       | 0.461       | 0.611| 0.653    |
| FC ≤ 4500| 0.615       | 0.615       | 0.615| 0.615    |
| FC ≤ 5000| 0.692       | 0.615       | 0.642| 0.653    |
| FC ≤ 5500| 0.692       | 0.538       | 0.6  | 0.615    |
| CRP ≤ 0.4| 0.769       | 0.461       | 0.588| 0.615    |
| CRP ≤ 0.6| 0.923       | 0.461       | 0.631| 0.692    |
| CRP ≤ 0.8| 0.923       | 0.384       | 0.6  | 0.653    |
| ΔFC ≤ 30 | 0.692       | 0.846       | 0.818| 0.769    |
| ΔFC ≤ 40 | **0.769**   | **0.846**   | **0.833** | **0.807** |
| ΔFC ≤ 50 | 0.769       | 0.969       | 0.769| 0.769    |
| ΔCRP ≤ 60| 0.615       | 0.846       | 0.8   | 0.73     |
| ΔCRP ≤ 70| 0.666       | 0.846       | 0.8   | 0.76     |
| ΔCRP ≤ 80| 0.666       | 0.769       | 0.727| 0.72     |

Discussion

To our knowledge, this is the first study to evaluate the utility of FC as a biomarker for predicting the clinical outcome during GMA in patients with active UC. In particular, FC showed efficacy as a biomarker in two respects: it was useful for predicting not only ER after GMA but also CR at the early phase during GMA.
Regarding the relationship between ER and the FC concentration after GMA, our results demonstrated that the FC concentration after GMA was able to assess ER and the therapeutic outcome of GMA without the need for any endoscopic procedure. Shimoyama et al. also reported that the FC level showed a positive relationship with the MES and could be used to assess the endoscopic disease activity at the end of GMA. In their study, although the cut-off value for assessing ER was not calculated, the median FC concentration in patients with mucosal healing was significantly lower than that in those with non-mucosal healing, which was consistent with our finding that the FC concentration after GMA was able to predict ER. Although the baseline characteristics and disease activity in their study were not markedly different from our study, the median FC concentration at entry in their study was markedly lower than that in our study. Labaere et al. reported that large quantitative differences of FC concentration were observed among various assays used in clinical practice. This discrepancy regarding FC concentrations between the present study and the study of Shimoyama et al. may be due to differences in measurement assays. The further standardization of FC measurement is needed in order to establish a unified cut-off value for assessing ER.

We also investigated the relationship between CR and time-dependent changes in the pMayo score, FC concentration, WBC count and CRP value during GMA. According to an ROC analysis, ΔFC at 1 week was the most accurate predictor of CR at the end of GMA. In the present study, a pMayo score cut-off value of 5 showed the same result as a ΔFC cut-off value of \( \leq 40\% \) at 1 week (Table 3). However, the pMayo score is a subjective marker, as it includes the Physician's global assessment, which is performed by each physician. One advantage of the pMayo score is that it is simple to determine; however, the physician's experience is extremely influential on the judgment of the general condition. Thus, the ΔFC at 1 week from starting GMA was shown to be the most accurate and objective predictor of the clinical outcome after GMA.

Previous reports have shown that patients who were most likely to respond to GMA tended to be first-episode cases who were steroid-naïve with a short disease duration and low disease activity. However, in our study, the disease duration in the CR group was significantly longer than that in the non-CR group, a finding that is completely opposite those of previous clinical trials. Furthermore, the rates of concomitant medication, such as corticosteroids, immunosuppressants and anti-TNF-α agents, did not differ between the CR and non-CR groups to a statistically significant extent. Thus, we suspect that assessing only the baseline characteristics before GMA therapy is not sufficient to predict CR, and a useful objective biomarker is important for evaluating the clinical efficacy of GMA.

Toyonaga et al. reported that FC measurement failed to predict the outcomes of remission induction therapy, including corticosteroids, anti-TNF-α agents and calcineurin inhibitors, in patients with active UC because of wide within-day variability. Turner et al. reported that FC levels in pediatric patients were unchanged at three days after intravenous steroid therapy. In contrast, De Vos et al. reported that the FC concentration at two weeks after remission induction therapy with infliximab was significantly lower in patients who achieved endoscopic remission than in those that did not. The mechanism underlying
the effects of GMA with an Adacolumn involves the selective removal of cell populations, including granulocytes, monocytes and macrophages, from the peripheral blood.\textsuperscript{(17)(18)} GMA is reported to decrease the mucosal level of neutrophils\textsuperscript{(30)} and the peripheral blood level of CD14(+)CD16(+) proinflammatory monocytes while concomitantly increasing the numbers of immature monocytes.\textsuperscript{(31)(32)} GMA would therefore decrease the number of neutrophils and macrophages in the intestinal mucosa via the Adacolumn, which adsorbs granulocytes and monocytes from the peripheral blood. In addition, the FC concentration is reportedly strongly correlated with the number of neutrophils in stool samples in patients with IBD.\textsuperscript{(33)} The early decrease in the FC concentration immediately after GMA in the present study might be a specific reaction associated with GMA.

The strength of the present study is its prospective design and the fact that it was conducted among multiple facilities, all of which employed the same protocol. However, it was associated with some limitations. Specifically, the study population was relatively small and we did not conduct histological assessments. Further investigations in larger cohorts will be needed to confirm the utility of FC as a biomarker.

**Conclusion**

In summary, we demonstrated the utility of FC as a biomarker for assessing ER after GMA and predicting CR at the early phase during GMA in patients with active UC. Assessing the baseline characteristics alone before GMA was not sufficient to predict CR. Our findings will benefit patients with active UC by allowing them to avoid undergoing unnecessary invasive procedures and will help establish new GMA therapeutic strategies.

**List Of Abbreviations**

UC: Ulcerative colitis; IBD: Inflammatory bowel diseases; FC: fecal calprotectin; GMA: granulocyte and monocyte adsorptive apheresis; FcγR: fragment crystallizable-gamma receptor; WBC: white blood cell; CRP: C reactive protein; pMayp: partial Mayo; MES: Mayo endoscopic subscore; CR: clinical remission; non-CR: non-clinical remission; ER: endoscopic remission; non-ER: non-endoscopic remission; IQRs: interquartile ranges; ROC: Receiver operating characteristics; AUC: area under the curve; PPV: positive predictive value; ΔFC: reduction rate of FC; ΔCRP: reduction rate of CRP

**Declarations**

**Ethics approval and consent to participate**

This multicenter prospective observational study was conducted by Asahikawa Kosei General Hospital, Asahikawa City Hospital and Asahikawa Medical University. The protocol was reviewed and approved by the Ethics Committees at Asahikawa Medical University (approved number 15106) and each institution.
All patients provided their written informed consent in accordance with the Declaration of Helsinki before commencement of this study.

Consent for publication

Not applicable

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Competing interests

Y. Sugiyama, Y. Kobayashi, Y. Murakami, T. Iwama, T. Sasaki, T. Kunogi, K. Takahashi, K. Tanaka, K. Ando, S. Kashima, Y. Inaba, K. Moriichi, H. Tanabe and Y. Saitho have no conflicts of interest to declare. N. Ueno has received personal fees from JIMRO Co. Ltd. M. Taruishi has received grants from JIMRO Co. Ltd. T. Okumura has received grants from AbbVie Inc, Astellas Pharma Inc., SHIONOGI Co. Ltd., Eisai co. Ltd. and Hokkaido Welfare Federation of Agricultural Cooperatives. M. Fujiya received grants from JIMRO Co. Ltd., and Kamui Pharma Inc.; grants and personal fees from AbbVie Inc, AYUMI Pharmaceutical Corporation, EA Pharma Co. Ltd., Janssen Pharmaceutical K.K., Kyorin Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Pfizer Inc, Takeda Pharmaceutical Co. Ltd., and ZERIA Pharmaceutical Co. Ltd.; and personal fees from Aspen Japan K.K., Kissei Pharmaceutical Co. Ltd., Olympus Co. Ltd.

Funding

This study was funded by JIMRO Co. Ltd., a satellite institution of Otsuka Pharmaceutical. Fecal calprotectin concentration of this study was measured by Thermo Fisher Scientific without compensation in a blind manner regarding the clinical information.

Authors' contributions

NU and MF developed study design. All authors treated UC patients in each hospital. YSu, YK, YM, TI, TK, KaT, KA, YI, MT collected all clinical data and calculated partial Mayo score. TS, KeT, KaT, KA, SK, YI, KM, HT, YSa performed endoscopy and calculated MES. NU analyzed and interpreted all clinical data. NU, TO and MF drafted manuscript and all author revised it. All authors have approved the final version of this manuscript.
Acknowledgements

The authors would like to appreciate the member of JIMRO and Thermo Fisher Scientific, and Naho Aizawa, for cooperation with conducting this study.

References

1. Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606–1619. doi:10.1016/S0140-6736(12)60150-0
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–1725. doi:10.1056/NEJMra1102942
3. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir. 1980;16 Suppl:273–282. doi:10.1016/b978-0-08-027379-2.50028-4
4. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47(4):506–513. doi:10.1136/gut.47.4.506
5. Tøn H, Brandsnes, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000;292(1–2):41–54. doi:10.1016/s0009-8981(99)00206-5
6. Lasson A, Stotzer PO, Öhman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9(1):26–32. doi:10.1016/j.crohns.2014.06.002
7. Lee SH, Kim MJ, Chang K, et al. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol. 2017;17(1):110. Published 2017 Oct 23. doi:10.1186/s12876-017-0669-7
8. Urushikubo J, Yanai S, Nakamura S, et al. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. World J Gastroenterol. 2018 Oct 14;24(38):4384–4392. doi:10.3748/wjg.v24.i38.4384. PMID: 30344422; PMCID: PMC6189847.
9. Magro F, Lopes J, Borralho P, et al. Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. Gut. 2019;68(4):594–603. doi:10.1136/gutjnl-2017-315545
10. Yamamoto T, Shiraki M, Bamba T, et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis. 2014;29(4):485–491. doi:10.1007/s00384-013-1817-3
11. Naganuma M, Kobayashi T, Nasuno M, et al. Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020;18(5):1102–1111.e5. doi:10.1016/j.cgh.2019.07.054
12. Toyonaga T, Kobayashi T, Nakano M, et al. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLoS One. 2017;12(9):e0185131. Published 2017 Sep 21. doi:10.1371/journal.pone.0185131

13. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010 Sep;59(9):1207-12. doi: 10.1136/gut.2010.211755. PMID: 20801771.

14. Molander P, af Björkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18(11):2011–2017. doi:10.1002/ibd.22863

15. Guidi L, Marzo M, Andrisani G, et al. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Dig Liver Dis. 2014;46(11):974–979. doi:10.1016/j.dld.2014.07.013

16. De Vos M, Dewit O, D’Haens G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis. 2012;6(5):557–562. doi:10.1016/j.jcrohns.2011.11.002

17. Hanai H, Takeda Y, Eberhardson M, et al. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163(1):50–58. doi:10.1111/j.1365-2249.2010.04279.x

18. Saniabadi AR, Tanaka T, Yamamoto T, et al. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34(1):51–60. doi:10.1002/jca.21670

19. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010;16(11):1905–1911. doi:10.1002/ibd.21260

20. Hibi T, Sameshima Y, Sekiguchi Y, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis. 2009;41(8):570–577. doi:10.1016/j.dld.2008.11.020

21. Yokoyama Y, Kawai M, Fukunaga K, et al. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. Published 2013 Feb 12. doi:10.1186/1471-230X-13-27

22. Iida T, Ikeya K, Kato M, et al. Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice. Digestion. 2017;96(2):119–126. doi:10.1159/000479502
23. Yamamoto T, Iida T, Ikeya K, et al. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis [published correction appears in Clin Transl Gastroenterol. 2018 Oct 8;9(10):192] [published correction appears in Clin Transl Gastroenterol. 2018 Nov 14;9(11):205]. Clin Transl Gastroenterol. 2018;9(7):170. Published 2018 Jul 6. doi:10.1038/s41424-018-0037-0

24. Kruis W, Dignass A, Steinhagen-Thiessen E, et al. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol. 2005;11(44):7001–7006. doi:10.3748/wjg.v11.i44.7001

25. Passalacqua S, Ferraro PM, Bresci G, et al. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. J Clin Apher. 2011;26(6):332–337. doi:10.1002/jca.20315

26. Sacco R, Romano A, Mazzoni A, et al. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study. J Crohns Colitis. 2013;7(12):e692-e697. doi:10.1016/j.crohns.2013.06.012

27. Dignass A, Akbar A, Hart A, et al. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis. 2016;10(7):812–820. doi:10.1093/ecco-jcc/jjw032

28. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135(2):400–409. doi:10.1053/j.gastro.2008.04.023

29. Labaere D, Smismans A, Van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J. 2014 Feb;2(1):30–7. doi: 10.1177/2050640613518201. PMID: 24918006; PMCID: PMC4040805.

30. Tanaka T, Okanobu H, Yoshimi S, et al. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis. 2008 Sep;40(9):731–6. doi: 10.1016/j.dld.2008.02.012. Epub 2008 Apr 2. PMID: 18387860.

31. Takeda S, Sato T, Katsuno T, et al. Adsorptive depletion of alpha4 integrin(hi)- and CX3CR1hi-expressing proinflammatory monocytes in patients with ulcerative colitis. Dig Dis Sci. 2010 Jul;55(7):1886–95. doi: 10.1007/s10620-009-0974-2. Epub 2009 Nov 12. PMID: 19908144.

32. Hanai H, lida T, Takeuchi K, et al. Adsorptive depletion of elevated proinflammatory CD14 + CD16 + DR ++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol. 2008 May;103(5):1210–6. doi: 10.1111/j.1572-0241.2007.01714.x. Epub 2008 Jan 2. PMID: 18177452.

33. Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999 Jan;34(1):50 – 4. doi: 10.1080/00365529950172835. PMID: 10048733.